



Rx ONLY

## **ZIKV Detect™ IgM Capture ELISA Instructions for Use**

**For Use Under an Emergency Use Authorization Only**

### **Purpose**

This document describes the use of an IgM antibody capture enzyme linked immunosorbent assay (MAC-ELISA) for the presumptive detection of antibodies to Zika virus in individuals meeting Centers for Disease Control and Prevention (CDC) clinical and/or epidemiological criteria for Zika virus testing.

---

### **INTENDED USE**

---

The ZIKV Detect™ IgM Capture ELISA is intended for the presumptive detection of Zika virus IgM antibodies in human sera collected from individuals meeting CDC Zika virus clinical criteria (e.g., a history of clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (e.g., history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiological criteria for which Zika virus testing may be indicated). The assay is intended for use in laboratories in the United States that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests, or by similarly qualified non-U.S. laboratories, consistent with the latest CDC guideline for the diagnosis of Zika virus infection.

Assay results are for the presumptive detection of IgM antibodies to Zika virus (ZIKV). Reactive results are not definitive for the diagnosis of Zika virus infection. False positive results are possible in patients with a history of infection with other Flaviviruses. Confirmation of the presence of anti-Zika IgM antibodies in presumptive positive specimens requires additional testing according to the latest CDC guideline for the diagnosis of Zika virus infection. Within the United States and its territories, laboratories are required to report presumptive positive results to the appropriate public health authorities.

Results of this test cannot be used as the sole basis of patient management decisions and must be combined with clinical observations, patient history, epidemiological information, and other laboratory evidences. Zika IgM levels over the course of illness are not well characterized. IgM levels are variable, may be detectable near day four post onset of symptoms and persist up to approximately 12 weeks following initial infection.

Negative results do not preclude the possibility of Zika virus infection, past or present. Negative results may be seen in specimens collected before day four post onset of symptoms or after the window of detectable IgM closes.

The ZIKV Detect™ IgM Capture ELISA is intended for use by trained laboratory personnel who are proficient in performing and interpreting immunoassays.

The ZIKV *Detect*<sup>TM</sup> IgM Capture ELISA is only for use under the FDA's Emergency Use Authorization.

## PROTOCOL USE LIMITATIONS

The ZIKV *Detect*<sup>TM</sup> IgM Capture ELISA described here has not been extensively tested with clinical specimens. Modifications of these assays (i.e., use of platforms or chemistries other than those described) are not permitted.

---

## SUMMARY AND EXPLANATION OF THE TEST

---

Zika virus disease (Zika) is a disease caused by Zika virus that is spread to people primarily through the bite of an infected mosquito from the *Aedes* genus, mainly *Aedes aegypti* in tropical regions. This is the same mosquito that transmits dengue, chikungunya, and yellow fever. Common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). The illness is usually mild with symptoms lasting for several days to a week after being bitten by an infected mosquito. The Zika virus was first discovered in 1947 and is named after the Zika forest in Uganda. In 1952, the first human cases of Zika were detected and since then, outbreaks of Zika have been reported in tropical Africa, Southeast Asia, and the Pacific Islands. Zika outbreaks have probably occurred in many locations but remain unrecognized because the symptoms are similar to many other diseases such as dengue and chikungunya. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infection in Brazil and on Feb. 1, 2016, the World Health Organization (WHO) declared Zika virus a public health emergency of international concern (PHEIC). Local transmission has been reported in many other countries and territories. Of major concern is the effect the Zika virus may have on pregnant women. Infection with Zika virus during pregnancy has been linked to congenital microcephaly and other brain defects in fetuses and infants. Sexual transmission of Zika virus is also of great concern and cases of individuals contracting the disease from their partners in the United States have been reported.

The ZIKV *Detect*<sup>TM</sup> IgM Capture ELISA tests for IgM antibodies in human serum.

---

## PRINCIPLE OF THE TEST

---

The ZIKV *Detect*<sup>TM</sup> IgM Capture ELISA is an enzyme linked capture immunoassay for the detection of human IgM antibodies targeting the ZIKV envelope glycoproteins. Polystyrene microtiter wells are pre-coated with polyclonal capture antibodies against human IgM. Positive Control, Negative Control, and unknown test samples are diluted into a sample dilution buffer and then added to the ELISA plate in appropriate locations (see Example Plate Layout). After incubation and washing, a subsequent Ready-To-Use (RTU) ZIKV antigen (Zika Ag), a Cross-reactive Control Antigen (CCA) and a Normal Cell Antigen (NCA) are added separately to each corresponding well. After a subsequent incubation step and wash step, an enzyme conjugate solution comprising horseradish peroxidase-labeled monoclonal anti-flavivirus antibody is added to each well. After washing, wells are incubated with a tetramethylbenzidine (TMB) substrate. An acidic Stop Solution is then added and the degree of enzymatic turnover is determined by the absorbance (optical density) measurement at 450 nanometers. If human IgM antibodies targeting the ZIKV envelope glycoproteins are present, a complex is formed

consisting of the IgM, antigen, and conjugate. If IgM antibodies targeting the ZIKV envelope glycoproteins are not present, then the antigen and conjugate are washed away.

---

## MATERIALS SUPPLIED

---

**Warning: Do not use any reagents where damage to the packaging has occurred.**

The ZIKV *Detect*<sup>™</sup> IgM Capture ELISA contains sufficient reagents for one plate of 96 wells (12 x 8 strips) for human IgM targeting Zika virus. This is sufficient for testing a maximum of 28 unknown samples for human IgM, with controls included in duplicate.

Below is a list of the kit contents.

- 1. Coated Microtiter Test Strips for IgM (1 plate containing twelve 1x8 strips for human IgM):** ELISA plate strip holder with 96 (12x8 strips) polystyrene microtiter wells pre-coated with capture antibodies specific for human IgM. Store at 2-8°C until expiry.
- 2. ZIKV IgM Negative Control (1x50µL):** The negative control aids in verifying the validity of the kit. Store at 2-8°C until expiry. Centrifuge briefly prior to use to sediment any precipitate.
- 3. ZIKV IgM Positive Control (1x50µL):** The positive control aids in verifying the validity of the kit. Store at 2-8°C until expiry. Centrifuge briefly prior to use to sediment any precipitate.
- 4. ZIKV Sample Dilution Buffer (1x25mL):** This buffer solution is used for diluting all serum samples and controls prior to testing in the ELISA. Store at 2-8°C until expiry.
- 5. Ready-To-Use ZIKV recombinant antigen for IgM (1x5mL):** This vial contains ready-to-use (RTU) ZIKV antigen (Zika Ag) that comprises the Zika envelope glycoproteins. Store at 2-8°C until expiry.
- 6. Cross-reactive Control Antigen for ZIKV IgM (1x5mL):** This vial contains a cross-reactive control antigen (CCA) cocktail. This is used to aid in the interpretation of the ELISA results. Store at 2-8°C until expiry.
- 7. Normal Cell Antigen for ZIKV IgM (1x5mL):** This vial contains a normal control antigen (NCA). This is used to aid in the interpretation of the ELISA results. Store at 2-8°C until expiry.
- 8. 100X Conjugate for ZIKV IgM (1x150µL):** This vial contains horseradish peroxidase-labeled monoclonal anti-Flavivirus antibody. Mix well prior to use. The 100X Conjugate is added to the Conjugate Diluent before use. Store the undiluted 100X conjugate at 2-8°C until expiry.
- 9. Conjugate Diluent for ZIKV (1x9mL):** This solution is used to dilute the 100X conjugate before adding to the ELISA plate. Store at 2-8°C until expiry.
- 10. 10X Wash Buffer (1x120mL):** One bottle of 10X concentrated Wash Buffer is used as directed in Test Procedure. Store at 2-8°C until expiry.
- 11. Liquid TMB Substrate (1x12mL):** Chromogenic substrate that reacts to horseradish peroxidase to generate the optical signal measured by the ELISA spectrophotometer. Store at 2-8°C until expiry.
- 12. Stop Solution (1x9mL):** Is used to terminate the reaction as directed in the Test Procedure. Store at 2-8°C until expiry.

**Caution:** strong acid, wear protective gloves, mask and safety glasses. Dispose of all the materials according to safety rules and regulations.

---

### MATERIALS AND EQUIPMENT REQUIRED BUT NOT SUPPLIED

---

- ELISA Spectrophotometer capable of absorbance measurement at 450 nm
- Biological or High-Grade Water
- Vacuum Pump
- Plate Washer
- 37°C Incubator without CO<sub>2</sub> supply or humidification
- 1-10 µL Single-Channel Pipettors, 50-200 µL and 200–1000 µL Single-and Multi-Channel Pipettors.
- Polypropylene tubes
- Parafilm
- Timer
- Vortex

---

### WARNING AND PRECAUTIONS

---

**FOR *IN VITRO* DIAGNOSTIC USE under the Emergency Use Authorization only.** A thorough understanding of the instructions for use is necessary for successful use of the product. Reliable results will only be obtained by using precise laboratory techniques and accurately following these instructions for use.

*Note:* In the case of specimens originating from regions with a known West Nile virus outbreak, an FDA-cleared West Nile virus IgM assay should be run in parallel with the ZIKV *Detect*<sup>™</sup> IgM Capture ELISA.

### SAFETY PRECAUTIONS

It is recommended that laboratories perform a risk assessment when conducting new tests and safety precautions should be based on the laboratory's risk assessment. If infection with chikungunya virus may be possible, then personnel should recognize that chikungunya virus produces high levels of viremia and serum from suspected chikungunya virus cases should be treated as potentially infectious even for serological procedures. Please review CDC guidance for state and local public health laboratories: <http://www.cdc.gov/zika/state-labs/index.html>

See the Biosafety in Microbiological and Biomedical Laboratories (BMBL) for additional biosafety information about these viruses and laboratory biosafety practices.

This procedure should be performed under laboratory safety conditions that take into consideration the potential infectious nature of the serum specimens involved. At a minimum, following heat inactivation, it is recommended that these procedures be performed using BSL-2 facilities and BSL-3 practices. To ensure safety of laboratory personnel, perform all sample manipulations within a Class II (or higher) Biological Safety Laboratory (BSL).

- All human source materials used in the preparation of controls have been either heat-inactivated or tested negative for antibodies to HIV 1&2, Hepatitis C and Hepatitis B surface antigen. However, no test method can ensure 100% efficiency. Therefore, all human controls and antigen should be handled as potentially infectious material. The Centers for Disease Control and Prevention and the National Institutes of Health recommend that potentially infectious agents be handled at Biosafety Level 2.
- Wear protective clothing, eye protection, and disposable gloves while performing the assay. Wash hands thoroughly afterwards.
- Do not eat, drink, smoke, or apply cosmetics where immunodiagnostic materials are being handled.
- Do not pipette by mouth.

### **TECHNICAL PRECAUTIONS**

- This test must be performed on serum only. The use of whole blood, plasma or other specimen matrix has not been validated.
- Do not mix various lots of any kit component within an individual assay.
- All reagents must be equilibrated to room temperature (20-25°C) before commencing the assay. The assay will be affected by temperature changes.
- Avoid repeated freezing and thawing of the serum specimens to be evaluated.
- While diluting the controls and test sera in sample dilution buffer for use in ELISA testing, it is critical that a **new pipette tip** be used for each sample to avoid cross contamination.
- All reagents are susceptible to contamination, thus, it is advisable to dispense reagents directly from bottles using clean pipettes or by carefully pouring. Pipettes should be used **only once** to avoid contamination of the components.
- Unused microwells must be resealed immediately and stored in the presence of desiccant. Failure to do so may cause erroneous results with those unused microwells.
- Do not use any component beyond the expiration date shown on its label.
- Avoid exposure of the reagents to excessive heat or direct sunlight during storage and incubation.
- Do not use a humidified incubator or a water bath for 37°C incubation steps. Doing so may lead to erroneous results.
- Some reagents may form a slight precipitate, mix gently before use.
- Incomplete washing will adversely affect the outcome and assay performance.
- To minimize potential assay drift due to variation in the substrate incubation time, care should be taken to add the stop solution into the wells in the same order and speed used to add the TMB solution.
- Avoid microbial contamination of reagents.
- Cover working area with disposable absorbent paper.

**WARNING:**  
**POTENTIALLY BIOHAZARDOUS MATERIAL**

This kit contains reagents made with human serum or plasma. The serum or plasma used has been heat inactivated unless otherwise stated. Handle all sera and kits used as if they contain infectious agents. Observe established precautions against microbiological hazards while performing all procedures and follow the standard procedures for proper disposal of specimens.

---

**SPECIMEN COLLECTION AND PREPARATION**

---

- Only serum should be used for this assay, and the usual precautions for venipuncture should be observed. Blood obtained by venipuncture should be allowed to clot at room temperature (20-25°C) for 30 to 60 minutes and then centrifuged according to the Clinical and Laboratory Standards Institute recommendations (CLSI Approved Guideline – Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests).
- Testing should be performed as soon as possible after collection. Do not leave sera at room temperature for prolonged periods. Separated serum should remain at 20-25°C for no longer than 8 hours. If assays are not completed within 8 hours, serum should be refrigerated at 2-8°C. If assays are not completed within 48 hours, or the separated serum is to be stored beyond 48 hours, serum should be frozen at or below -20°C.
- Avoid repeated freezing and thawing of samples since this can cause analyte deterioration. Frost-free freezers are not suitable for sample storage.
- Frozen samples should be thawed to room temperature and mixed thoroughly by gentle swirling or inversion prior to use. Always quick spin before use.
- If sera are to be shipped, they should be packed in compliance with Federal Regulations covering transportation of infectious agents.
- Do not use sera if any indication of microbial growth is observed.

---

**TEST PROCEDURE**

---

**CAUTION:** *The test procedure must be strictly followed. Any deviations from the procedure may produce erroneous results. Bring all kit reagents and specimens to room temperature (20-25°C) before use. Thoroughly mix the reagents and samples before use by gentle inversion. For long-term storage, serum samples should not be repeatedly thawed and frozen more than three times. Sera should be further aliquoted in a smaller volume and stored at -20°C or colder.*

**PREPARATION OF REAGENTS**

- *Preparation of 1X Wash Buffer:*

Dilute the 10X Wash Buffer to 1X using Biological or High-Grade Water. To prepare a 1X wash buffer solution, mix 120 mL 10X Wash Buffer with 1080 mL distilled (or deionized) water and rinse out any crystals. Swirl until well mixed and all crystals are dissolved. After diluting to 1X, store at room temperature for up to 6 months. Check for contamination prior to use. Discard if contamination is suspected.

- **Microtiter Strip Wells:**

Select the number of coated wells required for the assay. The remaining unused wells should be placed back into the pouch quickly, sealed, and stored at 2-8°C until ready to use or expiration.

- **Preparation of Conjugate Solution:**

Add 90 µL of 100X Conjugate for ZIKV IgM directly to the 9 mL bottle of Conjugate Diluent for ZIKV (1 part : 100 parts). Mix by inverting solution several times. This solution may be stored for up to 2 weeks if stored at 2-8°C. After 2 weeks, this conjugate solution should be discarded and no longer used in this assay. Please note that smaller volumes of the 100X Conjugate may be diluted into the corresponding volume of Conjugate Diluent (1 part: 100 parts), particularly if the storage time is expected to exceed 2 weeks or if the number of samples to be tested is low. Undiluted 100X Conjugate for ZIKV IgM that is stored at 2-8°C is stable for the duration of the kit shelf life.


### **ASSAY PROCEDURE**

1. Positive and negative controls must be assayed in duplicate with the Zika Ag, CCA and NCA portions of assay. Unknown serum samples to be tested are initially assayed singly and must be assayed with the Zika Ag, CCA and NCA. See the Example Plate Layout at the end of these instructions for use.
2. Mark the microtiter strips to be used.

Using a new pipette tip each time, dilute test sera and controls to 1/100 using the provided Sample Dilution Buffer. Use small polypropylene tubes for these dilutions and at least 4 µL of sera and positive and negative controls. For example: mix 4 µL of serum sample plus 396 µL of ZIKV Sample Dilution Buffer to make a 1/100 dilution.

3. Apply 50 µL per well of 1/100 diluted test sera, ZIKV IgM Negative Control, and ZIKV IgM Positive Control to the plate by single or multi-channel pipetter as appropriate. Apply specimens at the appropriate locations on the plate. Cover the plate with parafilm just on the well opening surface, so the bottom of the plate is not covered.

**Note:** This is to ensure even temperature distribution in all wells from bottom and sides; any extra parafilm can be cut off once the top is sealed to block evaporation.




4. Incubate the plate at 37°C for 1 hour in an incubator. **Note:** Do not stack plates on top of each other. They should be spread out as a single layer. This is very important for even temperature distribution. Do not use CO<sub>2</sub> or other gas incubators. Do not place plates in contact with any wet substances such as wet paper towels

**INCORRECT METHOD**



**CORRECT METHOD**



5. After the incubation, wash the plate 6 times with an automatic plate washer using 1X wash buffer. Use 300  $\mu$ L per well in each wash cycle.
6. Add 50 $\mu$ L per well of Zika Ag, 50 $\mu$ L per well of CCA and 50 $\mu$ L per well of NCA by multi-channel pipetter. Please see the **Example Plate Layout** for a sample method of sample placement and antigen addition.
7. Cover the plate with parafilm just on the well opening surface. The bottom of the plate should not be covered (see step 4).
8. Incubate the plate at 37°C for 1 hour in an incubator (see step 5).
9. After the incubation, wash the plate 6 times with an automatic plate washer using 1X wash buffer. Use 300  $\mu$ L per well in each wash cycle.
10. Prepare a fresh volume of Conjugate Solution (see Preparation of Reagents section) by diluting the appropriate volumes of 100X Enzyme Conjugate into the Conjugate Diluent (1 part : 100 parts).
11. Add 50  $\mu$ L per well of Conjugate Solution into all wells by multi-channel pipetter.
12. Cover the plate with parafilm just on the well opening surface. The bottom of the plate should not be covered (see step 4).
13. Incubate the plate at 37°C for 1 hour in an incubator (see step 5).
14. After the incubation, wash the plate 6 times with an automatic plate washer using 1X wash buffer. Use 300  $\mu$ L per well in each wash cycle.
15. Add 75  $\mu$ L/well of Liquid TMB substrate into all wells using a multi-channel pipetter.
16. Incubate the plate at room temperature (20-25°C) in a dark place (or container) for 10 minutes without any cover on the plate.



17. After the incubation, add 50µL/well of Stop solution into all wells by multi-channel pipetter and incubate at room temperature for 1 minute without cover on the plate.
18. After the incubation, read the **RAW** OD 450 nm (optical density at 450 nm) value with a microplate reader. **Do NOT subtract or normalize for any blank values or wells. Do NOT use a reference wavelength.** This may result in low CCA and NCA values and incorrect ISR values.

**\*\*\*Please make sure the microplate reader does NOT subtract or normalize for any blank values or wells.\*\*\***

---

### QUALITY CONTROL

---

The control material to be used with the ZIKV *Detect*<sup>TM</sup> IgM Capture ELISA test includes positive and negative control sera. Positive and negative controls must be run in duplicate on each plate tested. Acceptable Zika Immune Status Ratio (Zika ISR) values for these controls are shown below. The negative and positive controls are intended to monitor for substantial reagent failure. The test is invalid and must be repeated if either of the controls do not meet the specifications. If the test is invalid, patient results cannot be reported. Quality Control (QC) requirements must be performed in conformance with local, state, and/or federal regulations or accreditation requirements and the user's own laboratory's standard QC procedures. It is recommended that the user refer to CLSI C24-A and 42 CFR 493.1256 for guidance on appropriate Quality Control practices.

The raw materials used in the positive and negative controls are purchased through various commercial sera vendors. However, these sera are processed and titrated by InBios International for each ZIKV *Detect*<sup>TM</sup> IgM Capture ELISA kit lot. Users must use the controls provided by InBios to validate all runs.

The results below are given strictly for guidance purposes only. Analysis is applicable when using RAW spectrophotometric readings only and where automatic subtraction of water or reagent blanks is not employed.

**Calculation of the Negative Control:** Calculate the mean ZIKV IgM Negative Control values with Zika Ag, the CCA and the NCA:

***ZIKV IgM Negative Control Example***

|             | OD <sub>450</sub> |            |            |
|-------------|-------------------|------------|------------|
|             | <u>Zika Ag</u>    | <u>CCA</u> | <u>NCA</u> |
| Replicate 1 | 0.108             | 0.103      | 0.095      |
| Replicate 2 | 0.092             | 0.110      | 0.089      |
| Sum         | 0.200             | 0.213      | 0.184      |

Average Zika Ag =  $0.200 \div 2 = 0.100$

Average CCA =  $0.213 \div 2 = 0.107$

Average NCA =  $0.184 \div 2 = 0.092$

Use the average values to perform the following calculations:

Calculate the Zika Ag/CCA Ratio (Zika ISR)  $\equiv$  Zika Ag  $\div$  CCA:

$$0.100 \div 0.107 = \underline{0.935}$$

Calculate the Zika Ag/NCA Ratio  $\equiv$  Zika Ag  $\div$  NCA:

$$0.100 \div 0.092 = \underline{1.087}$$

Calculate the CCA/NCA Ratio  $\equiv$  CCA  $\div$  NCA:

$$0.107 \div 0.092 = \underline{1.163}$$

**Calculation of the Positive Control:** Calculate ZIKV IgM Positive Control values with the Zika Ag, the CCA and the NCA:

***ZIKV IgM Positive Control Example***

|             | OD <sub>450</sub> |            |            |
|-------------|-------------------|------------|------------|
|             | <u>Zika Ag</u>    | <u>CCA</u> | <u>NCA</u> |
| Replicate 1 | 1.121             | 0.160      | 0.121      |
| Replicate 2 | 1.205             | 0.152      | 0.105      |
| Sum         | 2.326             | 0.312      | 0.226      |

Average Zika Ag =  $2.326 \div 2 = 1.163$

Average CCA =  $0.312 \div 2 = 0.156$

Average NCA =  $0.226 \div 2 = 0.113$

Use the average values to perform the following calculations:

Calculate the Zika Ag/CCA Ratio (Zika ISR)  $\equiv$  Zika Ag  $\div$  CCA:

$$1.163 \div 0.156 = \underline{7.455}$$

The values in the table below must be obtained in order to report results of the assay. Non-fulfillment of these criteria is an indication of deterioration of reagents or an error in the test procedure and the assay must be repeated.

| <b>Factor (For Assay Verification)</b>                                 | <b>Tolerance</b> |
|--|------------------|
| Mean Negative Control OD <sub>450</sub> with Zika Antigen, CCA and NCA | < 0.300          |
| Mean Positive Control OD <sub>450</sub> in Zika Antigen                | > 0.300          |
| Positive Control Zika Immune Status Ratio (Zika ISR)                   | > 3.00           |
| Negative Control Zika Immune Status Ratio (Zika ISR)                   | < 1.60           |
| Negative Control CCA/NCA Ratio   | < 1.60           |

---

## INTERPRETATION OF RESULTS

---

The ZIKV *Detect*<sup>™</sup> IgM Capture ELISA kit provides two critical controls in order to aid in the discrimination between those specimens that have IgM antibodies to Zika virus and those specimens that may have IgM antibodies targeting a related flavivirus.

For clarity, we provide definitions of relevant terms below:

### **DEFINITIONS**

**Zika Ag OD<sub>450</sub>:** This is the raw OD<sub>450</sub> value obtained with a specimen using the Zika Ag.

**CCA OD<sub>450</sub>:** This is the raw OD<sub>450</sub> value obtained with a specimen using the CCA.

**NCA OD<sub>450</sub>:** This is the raw OD<sub>450</sub> value obtained with a specimen using the NCA.

**Zika Ag/CCA (Zika ISR):** This is the ratio of the Zika Ag OD<sub>450</sub> to the CCA OD<sub>450</sub>. That is, Zika ISR = Zika Ag OD<sub>450</sub> ÷ CCA OD<sub>450</sub>.

**Zika/NCA Ratio:** This is the ratio of the Zika Ag OD<sub>450</sub> to the NCA OD<sub>450</sub>. That is, Zika Ag OD<sub>450</sub> ÷ NCA OD<sub>450</sub>.

**CCA/NCA Ratio:** This is the ratio of the CCA OD<sub>450</sub> to the NCA OD<sub>450</sub>. That is, CCA OD<sub>450</sub> ÷ NCA OD<sub>450</sub>.

Properly interpreting specimen data includes the following steps:

- (1) Determine the Zika ISR value for each specimen.
- (2) Evaluate the Zika ISR value and determine the *preliminary* sample status as “Reactive for Zika IgM”, “NCA Analysis Required” or “Re-Test”. See ***Zika Interpretation Table***. If a sample is considered “Reactive for Zika IgM”, no further analysis is required.
- (3) Determine if a sample falls in the “Re-Test” range. If the sample is considered “Re-Test”, the specimen should be re-run according to the instructions for use in duplicate using Zika Ag, CCA and NCA. The Zika ISR is then re-calculated using the average values from the duplicate re-test run and interpreted according to the ***Zika Interpretation Table***.
- (4) If a sample is considered “NCA Analysis Required”, then calculate both the Zika Ag ÷ NCA Ratio and the CCA ÷ NCA Ratio. NCA Analysis will also be necessary for a “Re-Test” specimen whose average Zika ISR after re-testing is < 1.70.
- (5) Evaluate results using the ***Zika Interpretation Table***.

Zika Interpretation Table

| ISR Analysis |                               |   | NCA Analysis             |   | Result Interpretation and Follow-up Testing   |   |
|--------------|-------------------------------|---|--------------------------|---|---|---|
| Zika ISR     | Initial Result                | Zika ISR After Re-Test  | Zika/NCA                 | CCA/NCA   | Final Interpretation*   | Follow-up Testing   |
| ≥1.80        | Reactive for Zika IgM         | No Re-Test Required   | No NCA Analysis Required | No NCA Analysis Required  | <u>Presumptive Zika Positive</u><br><br>Presence of detectable Zika IgM antibody, possible recent infection with ZIKV | The result should be confirmed by the latest CDC guideline for the diagnosis of Zika virus infection. |
| 1.80 - 1.60  | <u>Re-Test (in Duplicate)</u> | Mean ≥1.70<br>Reactive for Zika IgM<br>(No NCA Analysis Required) |                          |   |   |   |
|              |                               | Mean <1.70<br><br>(NCA Analysis Required)                         | ≥1.70                    | ≥1.70   | <u>Possible Zika Positive<sup>†</sup></u><br><br>Zika virus IgM: Detected<br>Flavivirus IgM: Detected                 | The result should be confirmed by the latest CDC guideline for the diagnosis of Zika virus infection. |
|              |                               |   |                          | <1.70   | <u>Possible Zika Positive<sup>†</sup></u><br><br>Zika virus IgM: Detected<br>Flavivirus IgM: Not Detected             | The result should be confirmed by the latest CDC guideline for the diagnosis of Zika virus infection. |
|              |                               |   | <1.70                    | ≥1.70   | <u>Presumptive Other Flavivirus Positive</u><br><br>Zika virus IgM: Not Detected<br>Flavivirus IgM: Detected          | The result should be confirmed with FDA-cleared Dengue and West Nile virus IgM devices.               |
|              |                               | <1.70   |                          | <u>Negative</u><br><br>Zika virus IgM: Not Detected<br>Flavivirus IgM: Not Detected | None  |   |
| ≤1.60        | NCA Analysis Required         | No Re-Test Required   |                          | <1.70   |   |   |

<sup>†</sup>Specimens that fall in this category may still have levels of Zika IgM antibody present in serum and follow-up testing is required; however, other confounding IgM antibodies from related flaviviruses may be present that cause this level of reactivity.

\*All Zika virus IgM detected and Flavivirus IgM detected results are presumptive positive results.

For additional clarity, we provide four example specimens with sample data for evaluation:

|           | Zika Ag OD <sub>450</sub> | CCA OD <sub>450</sub> | NCA OD <sub>450</sub> |
|-----------|---------------------------|-----------------------|-----------------------|
| Sample #1 | 1.379                     | 0.085                 | 0.062                 |
| Sample #2 | 0.120                     | 0.946                 | 0.049                 |
| Sample #3 | 0.131                     | 0.416                 | 0.102                 |
| Sample #4 | 0.114                     | 0.099                 | 0.108                 |

### Step 1: Determine the specimen's Zika ISR

$$\text{Zika ISR} = \text{Zika Ag OD}_{450} \div \text{CCA OD}_{450}$$

The four example specimens would then have the following Zika ISR values:

|           | Zika ISR |
|-----------|----------|
| Sample #1 | 16.22    |
| Sample #2 | 0.13     |
| Sample #3 | 0.31     |
| Sample #4 | 1.15     |

### Step 2: Evaluate the specimen's Zika ISR

We first look at **ISR Analysis** columns of the **Zika Interpretation Table** to evaluate the initial result.

The four example specimens would then have the following *preliminary* interpretations:

|           | Preliminary Interpretation |
|-----------|----------------------------|
| Sample #1 | Reactive for Zika IgM      |
| Sample #2 | NCA Analysis Required      |
| Sample #3 | NCA Analysis Required      |
| Sample #4 | NCA Analysis Required      |

### Step 3: Determine if a sample falls in the “Re-Test” range

Reviewing the **Zika Interpretation Table** indicates that none of these example specimen values fall in the “re-test” range. Therefore, no duplicate testing would be required for any of these specimens.

|           | Duplicate testing required? |
|-----------|-----------------------------|
| Sample #1 | No                          |
| Sample #2 | No                          |
| Sample #3 | No                          |
| Sample #4 | No                          |

### Step 4: If the sample is considered “NCA Analysis Required”, then calculate both the Zika ÷ NCA Ratio and the CCA ÷ NCA Ratio

The four example specimens would then have the following ratios:

|           | Zika ÷ NCA Ratio                                    | CCA ÷ NCA Ratio                                     |
|-----------|---|---|
| Sample #1 | No NCA Analysis Required<br>(Reactive for Zika IgM) | No NCA Analysis Required<br>(Reactive for Zika IgM) |
| Sample #2 | 2.45 (0.120÷0.049)                                  | 19.31 (0.946÷0.049)                                 |
| Sample #3 | 1.28 (0.131÷0.102)                                  | 4.08 (0.416÷0.102)                                  |
| Sample #4 | 1.06 (0.114÷0.108)                                  | 0.92 (0.099÷0.108)                                  |

### Step 5: Evaluate the results using the Interpretation Table

Evaluate each ratio using the **Zika Interpretation Table**.

The four example specimens would then have the following *final* interpretations:

|           | Interpretation                               |
|-----------|--|
| Sample #1 | <u>Presumptive Zika Positive</u>             |
| Sample #2 | <u>Possible Zika Positive</u>                |
| Sample #3 | <u>Presumptive Other Flavivirus Positive</u> |
| Sample #4 | Negative                                     |

---

## LIMITATIONS

---

- This assay is for *in vitro* diagnostic use under FDA Emergency Use Authorization only and is limited to laboratories in the United States that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests, or by similarly qualified non-U.S. laboratories.
- All reactive samples must be confirmed by using the latest CDC guideline for diagnosis of Zika virus infection. Review the latest information on diagnosis of Zika virus disease at the CDC website: <http://www.cdc.gov/zika/laboratories/lab-guidance.html>.
- The presence of false positive and false negative results must be considered.
- Assay performance characteristics have not been established for visual result determination.
- Assay performance characteristics have not been established for matrices other than serum.
- Results from immunosuppressed patients must be interpreted with caution.
- The presence of RF (rheumatoid factor) may result in reduced reactivity in the ELISA and should be considered as a potentially interfering substance.
- Assay results should be interpreted by a trained professional only in the context of other laboratory findings, patient's history, and clinical signs and symptoms.

---

## PERFORMANCE CHARACTERISTICS

---

### Cross-Reactivity:

The potential cross-reactivity with IgM that would be present for other diseases was evaluated by testing specimens from patients with confirmed IgM antibodies to other microorganisms which could potentially cause false positive results. This cross-reactivity evaluation was composed of IgM positive sera against organisms whose infection produces symptoms similar to those observed at the onset of Zika virus infection and also viral strains which have a significant likelihood to result in cross-reactivity due to genetic similarity with Zika virus. Also included were IgM positive sera against organisms/strains which are likely to be observed in the currently affected and endemic area (i.e., Brazil and South America) since these organisms/strains will be an important part of the differential diagnosis of Zika virus infection and sera from other disease states, such as autoimmune disease.

The ZIKV *Detect™* IgM Capture ELISA kit was tested against 128 samples, including 32 flavivirus IgM positive specimens, 65 IgM positive specimens from patients with other non-Flavivirus diseases, and 24 specimens containing Anti-Nuclear Antibodies, Rheumatoid Factor, or Anti-Mouse Antibodies. An additional 7 yellow fever vaccine recipients were included for this study. The study results are summarized in the following table.



|   | Disease/ Infectious agent Positive Sera           | # of samples | # Zika IgM Reactive | # Zika/NCA $\geq 1.70$ | # CCA/NCA $\geq 1.70$ |
|---|---|--------------|---------------------|------------------------|-----------------------|
| Other disease present (IgM Positive)          | Anti-Chikungunya virus                            | 8            | 0                   | 0                      | 0                     |
|   | Anti-Cytomegalovirus (CMV)                        | 10           | 0                   | 0                      | 0                     |
|   | Anti-Epstein Barr Virus (EBV) –CA                 | 15           | 0                   | 0                      | 0                     |
|   | Anti-Parvovirus B19                               | 5            | 0                   | 0                      | 0                     |
|   | Anti-Varicella zoster virus                       | 10           | 0                   | 0                      | 0                     |
|   | Anti-nuclear Antibodies (ANA)                     | 10           | 0                   | 0                      | 0                     |
|   | Rheumatoid Factor                                 | 11           | 0                   | 0                      | 0                     |
|   | HAMA (human anti-mouse antibody)                  | 3            | 0                   | 0                      | 0                     |
|   | Anti-Malaria/anti- <i>plasmodium falciparum</i> * | 7            | 0*                  | 0                      | 0                     |
|   | Anti-Hepatitis (C) virus                          | 10           | 0                   | 0                      | 0                     |
| Flavivirus Specimens (non-Zika, IgM Positive) | Anti-Dengue virus**                               | 14           | 0                   | 14                     | 14                    |
|   | Anti-West Nile Virus***                           | 13           | 0                   | 13                     | 13                    |
|   | Anti-Japanese Encephalitis                        | 1            | 0                   | 0                      | 1                     |
|   | Anti-Saint Louis encephalitis (SLE)               | 4            | 0                   | 0                      | 3                     |
| Immunization to flavivirus                    | Yellow fever virus post-immunization              | 7            | 0                   | 2                      | 3                     |

\* One specimen result was initially scored as “Re-Test” but was not Zika IgM Reactive after duplicate testing

\*\* Average Zika/NCA = 6.24; Average CCA/NCA = 20.27

\*\*\* Average Zika/NCA = 4.34; Average CCA/NCA = 21.49

None of the 65 other non-Flavivirus IgM specimens were scored as Reactive for Zika IgM (i.e., *Presumptive Zika Positive*) in the ZIKV *Detect™* IgM Capture ELISA (one Malaria specimen was initially scored as Re-Test). Zika ISR, Zika/CCA, and CCA/NCA for all specimens were < 1.70.

None of the 32 IgM flavivirus specimens were scored as Reactive for Zika IgM (i.e., *Presumptive Zika Positive*) in the ELISA kit. However, the Zika/NCA and CCA/NCA ratios for most specimens were  $\geq 1.70$  and these specimens would be considered *Possible Zika Positive*. It is of note that the average CCA/NCA ratio was much greater than the average Zika/NCA ratio.

## Clinical Evaluation:

### Testing of Clinical Specimens:

The performance of the InBios ZIKV *Detect*<sup>™</sup> IgM Capture ELISA was evaluated with 55 clinical specimens characterized by testing with the authorized CDC Zika MAC-ELISA and PRNT or the CDC Trioplex rRT-PCR for Dengue and Zika viruses.

Additionally, the ELISA kit was evaluated with paired serum samples collected from 21 individuals (42 total samples) that were collected during acute and convalescent time points. All acute samples were confirmed Zika positive by an FDA-authorized PCR assay. The mean number of days post onset of symptoms was ~2.2 days (range 1 – 5 days). The mean number of days post onset of symptoms for the convalescent sample was ~15.9 days (range 6 – 80 days). The CDC Zika MAC-ELISA detected all 21 convalescent specimens as positive Zika IgM samples. The InBios ZIKV *Detect*<sup>™</sup> IgM Capture ELISA detected all 21 individuals at the convalescent time point (categorized as “*Presumptive Zika Positive*”). Additionally, three individuals were considered reactive with the InBios ZIKV *Detect*<sup>™</sup> IgM Capture ELISA at the acute phase (days 1, 4 and 5 post onset of symptoms). None of the samples tested in the “Re-Test” range.

An additional 86 normal serum samples (NHS) from a non-endemic Zika virus region were included in the study as additional negative specimens.

The results from the InBios ZIKV *Detect*<sup>™</sup> IgM Capture ELISA were compared to the reference results as follows. A sample was classified as “Zika Positive” when the CDC Zika MAC-ELISA result was positive/equivocal and confirmed by PRNT as Zika or when rRT-PCR was positive for Zika and an acute or convalescent specimen was also positive by the CDC Zika MAC-ELISA. A sample was classified as “Flavivirus Positive” when the CDC Zika MAC-ELISA result was positive/equivocal and PRNT could not distinguish Zika from other flaviviruses. A sample was scored as “Negative” when the CDC Zika MAC-ELISA result was negative. The summary results are shown in the table below.

|   |  |   | CDC MAC-ELISA / PRNT / PCR |              |          |                |
|---|--|---|----------------------------|--------------|----------|----------------|
|   |  |   | Zika +                     | Flavivirus + | Negative | Total          |
| InBios ZIKV<br><i>Detect™</i> IgM<br>Capture<br>ELISA | Presumptive Zika Positive<br>(Zika ISR $\geq$ 1.70 ) |   | 37                         | 15           | 0        | 52             |
|   | NCA Analysis   | Zika/NCA $\geq$ 1.70<br>CCA/NCA $\geq$ 1.70 | 0                          | 4            | 4        | 8 <sup>†</sup> |
|   |  | Zika/NCA $\geq$ 1.70<br>CCA/NCA $<$ 1.70    | 0                          | 0            | 0        | 0              |
|   |  | Zika/NCA $<$ 1.70<br>CCA/NCA $\geq$ 1.70    | 0                          | 0            | 4        | 4 <sup>†</sup> |
|   | Negative   |   | 0                          | 0            | 98       | 98*            |
|   | Total  |   | 37                         | 19           | 106      | 162            |

<sup>†</sup> Note: all 12 of these “NCA Analysis” specimens were considered positive for IgM antibodies to Dengue using the DENV *Detect™* IgM Capture ELISA. 9 out of 12 of these specimens were PCR positive for Dengue virus. All 12 samples also had a CCA ÷ NCA ratio  $\geq$  1.70.

\* Note: this includes 86 normal human serum samples that were evaluated.

This estimates the following:

|   |                               |
|---|-------------------------------|
| Positive Percent Agreement for Zika                       | 100% (37/37, 90.6% - 100%)    |
| Positive Percent Agreement for Zika <b>AND</b> Flavivirus | 100% (56/56, 93.6% - 100%)    |
| Negative Percent Agreement                                | 92.5% (98/106, 85.8% - 96.1%) |

Interference testing: Potentially interfering substances commonly occurring in serum were evaluated with the ZIKV *Detect™* IgM Capture ELISA. Interfering substances included bilirubin (0.2mg/mL), hemoglobin (160mg/mL), albumin (150mg/mL) and cholesterol (5mg/mL). These interfering substances were spiked into low reactive (n=3) and normal human serum samples (n=3) to evaluate their impact on assay performance. None of the interfering substances caused a statistically significant change in the ISR value for either the low reactive samples or normal human serum samples evaluated and did not alter the interpretation results.

Additionally, 3 human anti-mouse antibody (HAMA) serum samples and 3 rheumatoid factor (RF) positive serum samples were acquired from commercial vendors. Each HAMA and RF sample was mixed with a Zika low reactive specimen (Zika ISR ~2.5) in the kit's sample dilution buffer (equivalent to a 1:1 dilution of the Zika sample: Interfering sample) and the assay was performed as instructed in this kit instructions for use. Of the 3 HAMA samples,

none altered the reactivity of the low positive. Of the 3 RF samples, 2 out of the 3 (66.7%) diminished the Zika ISR value substantially and one specimen was lowered enough to alter the sample from a “Presumptive Zika Positive” status to a “Negative” status.

| Interfering Substance | Concentration Tested | Effect on Low Reactive Specimens | Effect on Negative Specimens               |
|-----------------------|----------------------|----------------------------------|--|
| Bilirubin             | 0.2mg/mL             | None observed (0/3)              | None observed (0/3)                        |
| Hemoglobin            | 160mg/mL             | None observed (0/3)              | None observed (0/3)                        |
| Albumin               | 150mg/mL             | None observed (0/3)              | None observed (0/3)                        |
| Cholesterol           | 5mg/mL               | None observed (0/3)              | None observed (0/3)                        |
| HAMA                  | <i>varies</i>        | None observed (0/3)              | None observed (see cross-reactivity table) |
| RF                    | <i>varies</i>        | <i>Lowered reactivity (2/3)</i>  | None observed (see cross-reactivity table) |



InBios International, Inc.  
562 1<sup>st</sup> Ave. South, Suite 600  
Seattle, WA 98104 USA  
Toll Free USA- 1-866-INBIOS1  
206-344-5821 (International)  
[www.inbios.com](http://www.inbios.com)

## ***Example Plate Layout***

An example plate layout is shown below which indicates a method for screening 28 specimens against Zika Ag, CCA and NCA.

|                                     | 1                       | 2          | 3          | 4          | 5                                    | 6          | 7          | 8          | 9                       | 10                        | 11         | 12         |
|-------------------------------------|-------------------------|------------|------------|------------|--------------------------------------|------------|------------|------------|-------------------------|---------------------------|------------|------------|
| A                                   | <b>Positive Control</b> | Sample #5  | Sample #13 | Sample #21 | <b>Positive Control</b>              | Sample #5  | Sample #13 | Sample #21 | <b>Positive Control</b> | Sample #5                 | Sample #13 | Sample #21 |
| B                                   | <b>Positive Control</b> | Sample #6  | Sample #14 | Sample #22 | <b>Positive Control</b>              | Sample #6  | Sample #14 | Sample #22 | <b>Positive Control</b> | Sample #6                 | Sample #14 | Sample #22 |
| C                                   | <b>Negative Control</b> | Sample #7  | Sample #15 | Sample #23 | <b>Negative Control</b>              | Sample #7  | Sample #15 | Sample #23 | <b>Negative Control</b> | Sample #7                 | Sample #15 | Sample #23 |
| D                                   | <b>Negative Control</b> | Sample #8  | Sample #16 | Sample #24 | <b>Negative Control</b>              | Sample #8  | Sample #16 | Sample #24 | <b>Negative Control</b> | Sample #8                 | Sample #16 | Sample #24 |
| E                                   | Sample #1               | Sample #9  | Sample #17 | Sample #25 | Sample #1                            | Sample #9  | Sample #17 | Sample #25 | Sample #1               | Sample #9                 | Sample #17 | Sample #25 |
| F                                   | Sample #2               | Sample #10 | Sample #18 | Sample #26 | Sample #2                            | Sample #10 | Sample #18 | Sample #26 | Sample #2               | Sample #10                | Sample #18 | Sample #26 |
| G                                   | Sample #3               | Sample #11 | Sample #19 | Sample #27 | Sample #3                            | Sample #11 | Sample #19 | Sample #27 | Sample #3               | Sample #11                | Sample #19 | Sample #27 |
| H                                   | Sample #4               | Sample #12 | Sample #20 | Sample #28 | Sample #4                            | Sample #12 | Sample #20 | Sample #28 | Sample #4               | Sample #12                | Sample #20 | Sample #28 |
| Ready to Use ZIKV Antigen (Zika Ag) |                         |            |            |            | Cross-reactive Control Antigen (CCA) |            |            |            |                         | Normal Cell Antigen (NCA) |            |            |